Auclair Agnès, Cotecchia Susanna, Glowinski Jacques, Tassin Jean-Pol
Institut National de la Santé et de la Recherche Médicale U 114, Collège de France, 75231 Paris Cedex 05, France.
J Neurosci. 2002 Nov 1;22(21):9150-4. doi: 10.1523/JNEUROSCI.22-21-09150.2002.
It was found recently that locomotor and rewarding effects of psychostimulants and opiates were dramatically decreased or suppressed in mice lacking alpha1b-adrenergic receptors [alpha1b-adrenergic receptor knock-outs (alpha1bAR-KOs)] (Drouin et al., 2002). Here we show that blunted locomotor responses induced by 3 and 6 mg/kg d-amphetamine in alpha1bAR-KO mice [-84 and -74%, respectively, when compared with wild-type (WT) mice] are correlated with an absence of d-amphetamine-induced increase in extracellular dopamine (DA) levels in the nucleus accumbens of alpha1bAR-KO mice. Moreover, basal extracellular DA levels in the nucleus accumbens are lower in alpha1bAR-KO than in WT littermates (-28%; p < 0.001). In rats however, prazosin, an alpha1-adrenergic antagonist, decreases d-amphetamine-induced locomotor hyperactivity without affecting extracellular DA levels in the nucleus accumbens, a finding related to the presence of an important nonfunctional release of DA (Darracq et al., 1998). We show here that local d-amphetamine releases nonfunctional DA with the same affinity but a more than threefold lower amplitude in C57BL6/J mice than in Sprague Dawley rats. Altogether, this suggests that a trans-synaptic mechanism amplifies functional DA into nonfunctional DA release. Our data confirm the presence of a powerful coupling between noradrenergic and dopaminergic neurons through the stimulation of alpha1b-adrenergic receptors and indicate that nonfunctional DA release is critical in the interpretation of changes in extracellular DA levels. These results suggest that alpha1b-adrenergic receptors may be important therapeutic pharmacological targets not only in addiction but also in psychosis because most neuroleptics possess anti-alpha1-adrenergic properties.
最近发现,在缺乏α1b - 肾上腺素能受体的小鼠[α1b - 肾上腺素能受体基因敲除小鼠(α1bAR - KOs)]中,精神兴奋剂和阿片类药物的运动和奖赏效应显著降低或受到抑制(Drouin等人,2002年)。在此我们表明,α1bAR - KO小鼠中3和6 mg/kg的d - 苯丙胺诱导的运动反应减弱(与野生型(WT)小鼠相比,分别为 - 84%和 - 74%)与α1bAR - KO小鼠伏隔核中d - 苯丙胺诱导的细胞外多巴胺(DA)水平升高缺失相关。此外,α1bAR - KO小鼠伏隔核中的基础细胞外DA水平低于WT同窝小鼠( - 28%;p < 0.001)。然而,在大鼠中,α1 - 肾上腺素能拮抗剂哌唑嗪可降低d - 苯丙胺诱导的运动亢进,但不影响伏隔核中的细胞外DA水平,这一发现与DA的重要非功能性释放有关(Darracq等人,1998年)。我们在此表明,局部给予d - 苯丙胺在C57BL6/J小鼠中释放非功能性DA的亲和力相同,但幅度比Sprague Dawley大鼠低三倍以上。总之,这表明一种跨突触机制将功能性DA放大为非功能性DA释放。我们的数据证实了通过刺激α1b - 肾上腺素能受体,去甲肾上腺素能神经元和多巴胺能神经元之间存在强大的耦合,并表明非功能性DA释放在解释细胞外DA水平变化中至关重要。这些结果表明,α1b - 肾上腺素能受体不仅可能是成瘾治疗的重要药理学靶点,也是精神病治疗的重要靶点,因为大多数抗精神病药物具有抗α1 - 肾上腺素能特性。